Confidential Page: 1 TITLE: A Phase Ib/II Clinical Study of BBI608 
Administered with Paclitaxel  in Adult Patients with 
Advanced Malignancies
PROTOCOL NUMBER: BBI608-201 
STUDY DRUG: BBI608IND #: 100,887
SPONSOR:[LOCATION_011] Biomedical, Inc.
640 Memorial DriveCambridge, MA 02139Telephone: ([PHONE_1617] 
Fax: ([PHONE_1618] 
MEDICAL MONITOR: Matthew J. Hitron, MD 
SAFETY FAX: ([PHONE_1618] (US)SAFETY CONTACT: ([PHONE_1617] x8563 (US)DATE OF PROTOCOL:
DATE OF AMENDMENT 1: DATE OF AMENDMENT 2: DATE OF AMENDMENT 3:
DATE OF AMENDMENT 4:24 November 2010 
20 March 2013 27 March 201513 April 2018 
10 May 2018 
Confidentiality Statement
The information contained in this document is confidential and the proprietary property of [LOCATION_011] Biomedical, 
Inc.  Any unauthorized use or disclosure of such information wi thout the prior written authorization of [LOCATION_011] 
Biomedical, Inc. is prohibited.
Matthew J. Hitron , MD 
([PHONE_2880] (US)
([PHONE_1617] x8563 (US),
 (617 )674-6800 
 ([PHONE_1618] p ()
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 2SYNOPSIS
Study Title: A Phase Ib/II Clinical Study of BBI608 Administered with 
Paclitaxel in Adult Patients  with Advanced Malignancies
Study Number: BBI608-201
Study Phase: Ib/II
Study Drug BBI608, an investigational small molecule anticancer drug, that i s hypothesized 
to affect multiple oncogenic cellular pathways, including inhibition of the 
STAT3 pathway, which has been implicated in cancer stem cells vi ability.
Primary Objective: To determine the safety, tolerability and recommended Phase 2 d ose (RP2D) of 
BBI608 when administered with paclitaxel in adult patients with advanced 
malignancies
Secondary 
Objectives:To determine the pharmacokinetic profile of BBI608 and paclitaxe l when 
administered in combination.
To assess the preliminary anti-tumor activity of BBI608 when ad ministered in
combination with paclitaxel in patients with advanced malignancie s.
To assess the objective response rate (ORR), disease control ra te (DCR), 
progression free survival (PFS), and overall survival (OS) of p atients with 
selected tumor types treated wit h BBI608 in combination with pa clitaxel.
To determine the pharmacodynamics (biomarkers) of BBI608 when tu mor 
biopsy is possible.
Study Design: This is an open label, multi-center, dose escalation study of B BI608 administered 
in combination with a fixed dose of paclitaxel administered IV w eekly at 80
mg/m2given as a 1 hour infusion; A cycle will consist of daily and con tinuous 
oral administration of BBI608 for four weeks in combination wit h paclitaxel 
administered IV weekly on day 3, 10 and 17 of each 28 day cycle.  I f  
administration of paclitaxel is discontinued due to paclitaxel- related toxicities, 
the administration of BBI608 will be continued until disease pr ogression if 
tolerated. The doses of BBI608 will escalate in three patient co horts until a RP2D
is reached.  
Pharmacokinetics (PK) will be performed for patients enrolled at selected study 
sites in the first cycle of the study. 
Pharmacodynamic assessments will be performed in patients with a ccessible 
tumors when tumor biopsy is possible. 
Safety and tolerability of BBI608 in combination with paclitaxe l will be assessed 
for the duration of study treatment.  
Evaluation of preliminary anti-tumor activity of BBI608 in combi nation with 
paclitaxel will be performed at regular intervals while patients  remain on study. 
Study Population: This study is conducted in patients with advanced solid tumors for whom weekly 
paclitaxel is an acceptable option;  including, ovarian cancer, ca ncer, breast 
cancer, NSCLC, melanoma, and gastric and esophageal adenocarcino ma.
Currently the study is only enrolling patients with thymic carci noma.
All patients must have a histologically or cytologically confir med malignancy 
that is locally advanced, unresectable, metastatic, or recurren t.  
Other inclusion criteria for all patients include: age > 18 yrs. ; ECOG 
performance status of 1 or 0; m easurable disease; and adequate hepatic, renal, 
and bone-marrow function.   
Patients with the tumor types below must also meet the followin g tumor-type-
specific inclusion criteria:
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 3Ovarian Cancer Patients must have epi[INVESTIGATOR_12253], fallopi[CONTACT_1629] t ube or 
primary peritoneal cancer that also meets one of the following definitions: 
xPlatinum resistant: a response to platinum 
therapy followed by [CONTACT_894658] 6 months after completing therapy
xPlatinum refractory: best response of stable 
disease or progression during platinum therapy
AND
xMust have had  prior systemic treatment with a  
taxane
xMust have received no more than 5 prior 
systemic cytotoxic regimens i n  t h e  m e t a s t a t i c  
setting with an up-front regimen counted if there 
is recurrence within 6 months.
Melanoma Patients with BRAF wild-type melanoma, or with BRAF 
mutations that are not amenable to BRAF inhibitor therapy, who are candidates for immunotherapy:
xMust have received ipi[INVESTIGATOR_125].
Patients with melanoma positive for the V600E or V600K
BRAF mutation:
xMust have received at least one line of prior 
therapy with a BRAF-specific inhibitor; either 
alone or in combination.
Breast Cancer
(Triple Negative)Patients with estrogen receptor-negative (ER-), 
progesterone receptor-negative (PR-), and human 
epi[INVESTIGATOR_3506] 2-negative (Her2-)
breast cancer:  
xMust have received at least one prior 
chemotherapy regimen for locally advanced or 
metastatic disease
Non Small-Cell 
Lung CancerPatients with NSCLC (adenocarcinoma, squamous, or 
adenosquamous histopathology) that is specifically, stage 
IIIB not curable by [CONTACT_140955], or stage IV:
xMust have received at least one prior 
chemotherapy regimen for locally advanced or 
metastatic disease. 
xEGFR-positive or ALK-positive patients must 
have received at least one line of EGFR-directed 
therapy or ALK-directed therapy, respectively.
xMust have received prior taxane therapy.  
Esophageal/GEJ/
Gastric
AdenocarcinomaPatients with adenocarcinoma arising from the 
esophagus, gastro-esophag eal junction, or stomach:
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 4xMust have received prior treatment with a 
platinum/fluoropyrimidine-based therapy with 
or without an anthracycline in the metastatic 
setting; or, in the adjuvant setting if recurrence
occurred within 6 months of completing 
systemic adjuvant treatment.
Patients with HER2 positive tumors:
xMust have had prior treatment with a Her2 
inhibitor (e.g. traztuzumab or lapatinib)
Patients who have received prior taxane therapy may be 
enrolled.
Thymic CarcinomaPatients with thymic carcinoma:
xMust have received at least one prior systemic 
chemotherapy regimen for  metastatic, recurrent, 
locally advanced or otherwise unresectable disease.
In the phase [ADDRESS_1253557], Dose, 
and Mode of 
Administration: Patients in this trial will receive BBI608 orally at dose level s specified for their 
respective dose cohorts.  Administration of BBI608 bid will begi n at 500 mg for 
a total daily dose of 1000 mg/day (first cohort) and escalate until the RP2D or 
MTD is determined. When BBI608 is administered tid, the dose wil l start at 200 
mg for a total daily dose of 600mg/day and escalated until the RP 2D or MTD is 
determined. In each cycle BBI608 will be tak en daily for 4 weeks (28 days).   
BBI608 will be administered twice daily, one hour prior or two h ours after meals, 
with the first dose taken in the morning and doses separated by a pproximately 
12 hours.
On days 3, 10, and 17 of each 28 day cycle, patients will receiv e the 1 hour 
infusion of paclitaxel at 80 mg/m2at [ADDRESS_1253558] morning dose 
of BBI608. Cycles will be repeated until progression of disease,  unacceptable 
t o x i c i t y ,  o r  a n o t h e r  d i s c o n t i n u a t i o n  c r i t e r i o n  i s  m e t .   I n  t h e  case of toxicity, 
adjustment is permitted. If administration of paclitaxel is dis continued due to 
paclitaxel-related toxicity, the administration of BBI608 will be continued until 
disease progression if tolerated.
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 5Criteria for Dose 
Escalation:Enrollment at the next dose level and/or additional patients in to the ongoing 
cohort will occur according to the following criteria:
Æ”,I]HURWUHDWHGSDWLHQWVH[SHUL HQFHD'/7GHILQHGEHORZE\ 'D\RI
continuous daily dosing, then dose escalation will occur.
Æ”,IRQHWUHDWHGSDWLHQWH[SHULHQFHV a DLT (defined below) by [CONTACT_2006] 28 of 
continuous daily dosing, then an additional three patients will  be enrolled for a 
total of six patients treated at the same dose level.  Escalati on will occur if no 
additional DLTs are seen in that  cohort (one of six patients).
Æ”,IWZRRUPRUHWUHDWHGSDWLHQWVDWDGRVHOHYHOH[SHULHQFHD '/7E\'D\RI
continuous daily dosing, dose escalation will stop and an addit ional three patients 
will be enrolled for a total of six patients treated at the pri or dose level. 
The MTD is defined as the dose level at which no more than one out of six 
patients has an observable DLT. 
Duration of Treatment: For an individual patient, treatment with BBI608 and paclitaxel w ill continue 
until unacceptable toxicity, disease progression or another disc ontinuation 
criterion is met.  It is expected that the majority of patients will receive between 
one and four cycles of BBI608 and paclitaxel for a treatment peri od of four to 16 
weeks. 
Patients may continue protocol therapy or BBI608 alone beyond radio logic
progression provided there is no clinical deterioration.  
Criteria for 
Determination of 
Dose-Limiting Toxicity:A DLT is defined by [CONTACT_894659]608, or BBI608 in combination with pa clitaxel within 
28 days of treatment:
Æ” &7&$( &RPPRQ 7HUPLQRORJ\ &ULWHULD IRU $GYHUVH (YHQWV *UDGH 
hematological toxicity
Æ” * U D G H  R U  Q R Q -hematological toxicity, except Grade 3 or 4 
nausea/vomiting/anorexia, diarrhea or fatigue will be considered a  DLT only if 
it persists more than three (3) days despi[INVESTIGATOR_130122]; and 
alopecia will not b e considered a DLT
Æ”$Q\RWKHUWR[LFLW\WKDWLQWKHYLHZRIWKH3ULQFLSDO,QYHVWLJ DWRUUHSUHVHQWVD
clinically significant  hazard to the patient.
Whether a DLT has occurred will be assessed for each patient at  D a y  [ADDRESS_1253559] 28 days of BBI608 therapy.  DLT will be dete rmined from 
adverse events, changes from bas eline in physical examination f indings and 
laboratory parameters.  The incidence of adverse events and DLT s will be 
evaluated for each dose leve l and for all patients.  
Adverse events considered related to paclitaxel will not be cons idered DLTs.
Pharmacokinetic 
and 
Pharmacodynamic 
Variables:Pharmacokinetic variables to be determined include maximum plas ma drug 
concentration (Cmax), volume of distribution, area under the ti me-concentration 
curve (AUC), distribution half-l ife, and terminal half-life.  F or patients enrolled 
at select study sites, blood samples for PK determination will b e drawn on Day 
[ADDRESS_1253560] cycle for each dose level.  Respon se (increase or 
decrease) of several biomarkers from biopsied tumors following BBI608
administration will be examined in patient with accessible tumor s for biopsy .  
Tumor biopsies will be collected prior to the first dose of BBI [ADDRESS_1253561] signed the 
optional tumor biopsy consent.
Statistical Methods: All patients receiving at least one daily dose of BBI608 will b e considered 
evaluable for safety analyses.  In addition to the evaluation a nd categorization of 
adverse events, listin gs of laborator y test results collected at baseline and durin g 
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 6the study will be generated.  Des criptive statistics summarizin g the changes in 
those laboratory tests over time will be presented.
Patients who have received at least one cycle of BBI608 and hav e had at least 
one disease assessment following the initiation of therapy will  be considered 
evaluable for response.  The anti- tumor activity will be evaluated on an 
exploratory basis and will be summarized using descriptive stat istics or graphics.
For each tumor type, the following endpoints will be summarized : Objective 
response rate (ORR), defined as the proportion of patients with a documented 
complete response (CR) or partial response (PR) based on RECIST  1.1; Disease 
Control Rate (DCR), defined as the proportion of patients with documented CR, 
P R  a n d  s t a b l e  d i s e a s e  ( S D )  b a s e d  o n  R E C I S T  1 . 1 ;  p r o g r e s s i o n  f r e e survival 
(PFS); and overall survival (OS).
There is no statistical hypothesis testing in the Phase II part  a nd  t he  pl a n ne d 
sample size of Phase II (20 - 40 per cohort) is considered to be  clinically adequate 
to assess tolerability, safety, and preliminary anti-cancer act ivity of study drugs 
of interest, and actual sample size depends on the actual enrol lment in each arm.
Sample Size Justification for Thymic Carcinoma Cohort:
A total of 10 (minimum) to 15 (m aximum) patients will be target ed to this cohort 
and a Bayesian posterior probability approach will be employed t o monitor the 
enrollment based on the overall response rate (ORR) by [CONTACT_10585] 16.  After the first 
[ADDRESS_1253562] response evaluation, or withdraw, or die by [CONTACT_894660] 16, the 
Bayesian posterior probability of the ORR being greater than a target value will 
be continuously evaluated. If the posterior probability is grea ter than 70% or less 
than 20%, then further enrollment may be stopped. Otherwise enro llment will 
continue until the enrollment cap of [ADDRESS_1253563] the 
mean equal to the historically observed ORR of 0.22 (Lemma 2011 ).
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 7DOSE ESCALATION SCHEME
Phase Ib â€“ Three-subject Cohort Dose Escalation
GroupNo. 
Subjects#Dose 
LevelTotal Daily Dose 
of BBI608**Pharmacokinetics
(Week)
I-b 3 Level 1b 1000 mg+1*, 2, 3*, 4
II-b 3 Level 2b 1500 mg 1*, 2, 3*, 4
III-b 3 Level 3b 2000 mg 1*, 2, 3*, 4
         * Pharmacokinetic monitoring.
         # Groups may be expanded  to six subjects, as provided in the protocol.
**The total daily dose will be split into two approximately equa l sub-doses 
In the absence of disease progres sion and unacceptable toxicity , weekly dosing may continue. Restaging will 
occur after every 8 weeks of treatment.
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 8TABLE OF CONTENTS
SYNOPSIS....................................................... ............................................................... ...........2  
DOSE ESCALATION SCHEME......................................... .....................................................7  
TABLE OF CONTENTS.............................................. .............................................................8  
1 PRECLINICAL SUMMARY A ND STUDY RATIONALE ........................ ..................12  
1.1 Scientific Background of BBI608................................ ..........................................12  
1.2 Preclinical Efficacy........................................... .....................................................12  
1.3 GLP Toxicology................................................. ....................................................12  
1.4 Safety and Signs of Antitumo r Activity in Phase I.............. ..................................13  
2 STUDY OBJECTIVES............................................... .....................................................13  
2.1 Primary Objective .............................................. ....................................................13  
2.2 Secondary Objectives........................................... ..................................................13  
3 SELECTION OF STUDY POPULATION .................................. ...................................13  
3.1 Inclusion Criteria ............................................. ......................................................14  
3.2 Exclusion Criteria ............................................. .....................................................16  
3.3 Number of Patients ............................................. ...................................................16  
4 INVESTIGATIONAL PLAN........................................... ...............................................17  
4.1 Overall Study Design........................................... ..................................................17  
4.2 Rationale for Study Design..................................... ...............................................18  
4.3 Selection of Dose .............................................. .....................................................18  
4.4 Risk Benefit Assessment........................................ ................................................19  
4.5 Criteria for Dose Escalation and D etermination of Dose-Limiting  Toxicity ........19  
4.6 Dose-Limiting Toxicity ......................................... ................................................19  
4.7 Study Duration................................................. ......................................................19  
5 STUDY VISITS................................................... ............................................................20  
5.1 Informed Consent............................................... ....................................................20  
5.2 Pre-Study Evaluations (Baseline) ............................... ...........................................20  
5.3 On-Study Assessments........................................... ................................................20  
5.4 Tumor Evaluation Visits........................................ ................................................22  
5.5 End of Study Evaluation ........................................ ................................................23  
5.6 Discontinuation from Study..................................... ..............................................23  
6 STUDY PROCEDURES ............................................... ..................................................24  
6.1 Medical History ................................................ .....................................................24  
6.2 Physical Examination........................................... ..................................................24  
6.3 Clinical Laboratory Tests...................................... .................................................24  
6.4 Pharmacokinetic Assessments .................................... ...........................................24  
6.5 Pharmacodynamic Assessments .................................... ........................................25  
7 TREATMENT ...................................................... ...........................................................26  
7.1 BBI608......................................................... ..........................................................26  
7.2 Dose Modifications............................................. ...................................................27  
7.3 Treatment Compliance........................................... ................................................29  
7.4 Blinding....................................................... ...........................................................29  
7.5 Prior Treatment ................................................ ......................................................29  
7.6 Concomitant Medication......................................... ...............................................30  
8 SAFETY ASSESSMENTS............................................. .................................................31  
8.1 Adverse Events ................................................. .....................................................31  
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 98.2 Serious Adverse Events ......................................... ................................................32  
9 ASSESSMENT OF ANTI-TUMOR AC TIVITY IN SOLID TUMORS .............. ..........33  
9.1 Methods of Measurement ......................................... .............................................33  
9.2 Baseline Documentation of â€œTargetâ€ and â€œNon-Targetâ€ Lesions .... .....................[ADDRESS_1253564] Confidentiality ........................................ ..................................................41  
13.9  Monitoring ..................................................... ........................................................41  
13.10  Case Report Form (CRF) Completion .............................. .....................................42  
13.11  Final Site Report .............................................. ......................................................42  
13.12  Final Study Report ............................................. ....................................................42  
13.13  Use of Information............................................. ....................................................42  
13.14  Publication .................................................... .........................................................43  
13.15  Research Outside the Terms of this Protocol.................... .....................................43  
14 APPENDIX A:  SCHEDU LE OF ASSESSMENTS ........................... ............................44  
15 APPENDIX C:  PERFORMANCE STATUS ................................ .................................45  
16 APPENDIX D:  PHARMACOKINETIC STUDIES........................... ............................46  
17 APPENDIX E: TUMOR BIOPSIES ..................................... ..........................................50  
18 APPENDIX F: PACLITAXEL PRODUCT LABEL ........................... ...........................52  
19 SPONSOR SIGNATURE.............................................. ..................................................53  
20 INVESTIGATORâ€™S SIGNATURE ....................................... ..........................................54  
21 REFERENCES ..................................................... ...........................................................55
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 10LIST OF ABBREVIATIONS AN D DEFINITIONS OF TERMS
AE Adverse Event
ALT Alanine transaminase (SGPT)ANOVA Anal
ysis of variance
AP Alkaline phosphataseAST Aspartate transaminase (SGOT)AUC Area under the time-concentration curveBSA Bod
y surface area
BUN Blood urea nitro gen
CBC Complete blood countCDER Center for Dru
g Evaluation and Research
Cmax Maximum plasma dru g concentration
Cmin Minimum plasma dru g concentration
CFR Code of Federal Re gulations
CI Confidence intervalCR Complete responseCru Complete response / unconfirmedCRF Case report formCT Computed tomo
graphy
CV Coefficient of variationCTCAE Common terminolo
gy criteria for adverse events
DLT Dose limitin g toxicit y
ECOG Eastern Cooperative Oncolo gy Group
ECG Electrocardio gram
FDA Food and Dru g Administration
GCP Good Clinical PracticeGGT Gamma 
glutam yl transferase 
GLP Good Laborator y Practice
GMP Good Manufacturin g Practice
Hct HematocritHED Human equivalent doseH
gbH e m o globin
HGF Hepatoc yte growth factor
HIPAA Health Information Portabilit y and Accountabilit y Act
IC50 Inhibitor y concentration, 50%
ICH International Conference on HarmonisationIEC Independent Ethics CommitteeIND Investi
gational New Dru g
IRB Institutional Review BoardLD Lon
gest diameter
LDH Lactic deh ydrogenase
MR Minor responseMRI Ma
gnetic resonance ima ging
MTD Maximum tolerated doseNCI National Cancer Institute
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 11NOAEL No observable adverse effect level
NOEL No observable effect levelORR Overall response ratePD Pro
gressive disease
PK PharmacokineticPR Partial responseQD Once dail
y
RECIST Response evaluation c riteria in solid tumors
RP2D Recommended Phase 2 DoseRBC Red blood cell (count)SAE Serious adverse eventsCR Strin
gent complete response 
SD Stable disease SE Standard errorSGOT Serum 
glutamic oxaloacetic t ransaminase (AST)
SGPT Serum glutamic p yruvic transaminase (ALT)
SPEP Serum protein electrophoresisTmax Time to maximum plasma concentrationTNM scale Tumor node metastases scaleULN Upper limits of normalUPEP Urine protein electrophoresisVGPR Ver
y good partial response
WBC White blood cell (count)
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: [ADDRESS_1253565] uncovered the presence of cancer stem cells  (CSC, also called tumor initiating cells 
or cancer stem-like cells) which have self-renewal capability a n d  a r e  c o n s i d e r e d  t o  b e  
potentiallyresponsible for malignant growth, relapse and metast asis. Importantly, CSCs are inherently 
resistant to conventional therapi[INVESTIGATOR_014]. Therefore, a targeted agen t with activity against cancer stem cells 
for cancer patients is being explored (Lobo, Shimono et al. 2007;  Boman and Wicha, 2008;  Please find 
a list of updated reviews on cancer stem cells in all major can cer types in the special issue of Journal 
of Clinical Oncology on cancer stem cells (J Clin Oncol. 2008 Jun 10;26(17)).
BBI608 is a small molecule that is hypothesized to affect multi ple oncogenic cellular pathways, 
including inhibition of the STAT3 pathway. 
STAT3 is an oncogene that belongs to a family of transcription f actors activated in response to 
cytokines and/or growth factors to promote proliferation, survi val, and other biological processes.  
STAT3 activates certain genes involved in tumorigenesis, invasio n, and metastasis, including Bcl-xl, 
Akt, c-Myc, cyclin D1, VEGF, and survivin.  STAT3 is aberrantly active in a variety of human cancers, 
including in more than half of breast and lung cancers, hepatoc ellular carcinomas, and multiple 
myelomas and more than 95% of head/neck cancers. STAT3 ablation by [CONTACT_894661], survival, and metastasis. 
While essential for embryonic deve lopment, the deficiency of ST AT3 seems well tolerated in adult 
mice. Patients with Jobâ€™s syndrom e survive into adulthood with S TAT3 dominant negative mutations.
In a French registry study of 60 patients with Jobâ€™s syndrome, 93% were alive at age 50 (Chandesris et 
al, 2012).
Therefore, blocking STAT3 may target cancer stem cells as well a s the bulk of the heterogeneous cancer 
cells while potentially spare normal cells and normal adult stem c ells
1.2 Preclinical Efficacy
Cancer stem cells are intrinsically resistant (more than 5 to 1 0 fold) to chemotherapeutic drugs. BBI608 
has activity (~100 to 500 nM) against cancer stem cells in vitro while sparing normal hematopoietic 
stem cells (IC 50not reached at 30 PM) in vitro. BBI608 has demonstrated in vitro activity in human 
cancer cell lines derived from m ultiple tumor types with IC 50s ranging from 0.[ADDRESS_1253566] level (NOAEL, based on  clinical observation, laboratory tests, 
gross and histopathological chang es) for rats administered BBI60 8 daily orally over 28 days was 30 
mg/kg/day (human equivalent dose: 180 mg/m2) and the NOAEL in dogs a dministered BBI608 daily 
orally over 28 days was 30 mg/kg/day (human equivalent dose: 600  mg/m2).
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 131.4 Safety and Signs of Antit umor Activity in Phase I
A phase 1 dose escalation study (BBI608-101) in adult patients wit h advanced cancer was initiated to 
determine the safety, tolerab ility, recommended phase 2 dose (R P2D), pharmacokinetics and 
preliminary anti-tumor activity of BBI608. A modified Simon acc elerated titration scheme was used 
for dose escalation, with a cycle consisting of twice-daily ora l administration of BBI608 for 4 weeks, 
and was repeated every 4 weeks (28 days) until progression of di sease, unacceptable toxicity, or other 
discontinuation criteria were met.
The dose of BBI608 has been escalated from 20 mg to 2000 mg/day wh en BBI608 was taken bid, and 
MTD is not reached. The total daily dose has been escalated to 1500 mg (total daily dose) when BBI608 
was taken tid, and MTD is not reached. Further dose escalation is limited by [CONTACT_21173][INVESTIGATOR_894636].
Please refer to the Investigatorâ€™s  Brochure (version 6.3) for cur rent clinical data.
2 STUDY OBJECTIVES
2.1 Primary Objective
The primary objective of study is:
xTo determine the safety, tolerab ility and recommended Phase 2 d ose (RP2D) of BBI608 when 
administered orally daily in combination with paclitaxel in adu lt patients with advanced 
malignancies.
2.2 Secondary Objectives
The secondary objectives of the study are:
xTo determine the pharmacokinetic profile of BBI608 and paclitax el when administered in 
combination.
xTo assess the preliminary anti-tumor activity of BBI608 when ad ministered in combination 
with paclitaxel in patients with advanced malignancies.
xTo assess the objective response rate (ORR), disease control ra te (DCR), progression free 
survival (PFS), and overall survival (OS) of patients with sele cted tumor types treated with 
BBI608 in combination with paclitaxel.
xTo determine the pharmacodynamics (biomarkers) of BBI608.
[ADDRESS_1253567] cancer
NSCLC
MelanomaGastric
/GEJ/Esophageal Adenocarcinoma
Inclusion of other tumor types may be permitted upon agreement b etween investigators and the sponsor.
The study is currently enrolling only patients with thymic carc inoma. Specific enrollment criteria for 
this cohort is detailed in section 3.1.
The study will be conducted at multiple sites in Canada and the Un ited States.
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 143.[ADDRESS_1253568] be obtained and documente d according to 
International Conference on Harmonization (ICH)- Good Clinical Pr actice (GCP), the local 
regulatory requirements, and permission to use private health i nformation in accordance with 
the Health Insurance Portability  and Accountability Act (HIPAA)  prior to study-specific 
screening procedures
2. A histologically or cytologically confirmed ovarian, breast, n on-small cell lung, melanoma, 
gastric/GEJ/esophageal or other type of advanced cancer* that is metastatic, unresectable, or 
recurrent and for which weekly paclitaxel is an acceptable ther apeutic option.
3. Patients with epi[INVESTIGATOR_546763] n, fallopi[INVESTIGATOR_8916], or primary p eritoneal cancer must also meet 
the following criteria:
a. Must be either platinum-resista nt or platinum-refractory acco rding to the following 
definitions:
1. Platinum-resistant: a response to platinum therapy followed by [CONTACT_894662] 6 months after completing therapy
2. Platinum-refractory: best response of stable disease or progr ession during  
platinum therapy
b. Must have had prior systemic treatment with a taxane
c. Must have received no more than [ADDRESS_1253569] al so meet the following criteria:
a. If melanoma is BRAF wild-type or has BRAF mutations that are no t amenable to 
BRAF inhibitor therapy, and the patient is a candidate for immun otherapy, must have 
received ipi[INVESTIGATOR_125].
b. If melanoma is positive for the V600E or V600K BRAF mutation, must have received 
at least one line of prior therapy with a BRAF-specific inhibit or; either alone or in 
combination.
5. Patients with triple negative breast cancer (estrogen recepto r-negative (ER-), progesterone 
receptor-negative (PR-), and human epi[INVESTIGATOR_205928] 2-negative (Her2-) must 
also meet the following criteria:
a.Must have received at least one prior chemotherapy regimen for l ocally advanced or 
metastatic disease.
6. Patients with NSCLC (adenocar cinoma, squamous, or adenosquamo us histopathology) must 
also meet the following criteria:
a. Must have disease that is stage IIIB, not curable by [CONTACT_140955], or stage
IV.
b. Must have received at least one prior chemotherapy regimen fo r locally advanced or 
metastatic disease. 
c. EGFR-positive or ALK-positive patients must have received at l east one line of EGFR-
directed or ALK-directed therapy, respectively.
d. Must have received prior taxane therapy.
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 157. Patients with adenocarcinoma ar ising from the esophagus, gast ro-esophageal junction, or 
stomach must also meet the following criteria:
a. Must have received prior treatment with a platinum/fluoropyrim idine-based therapy 
with or without an anthracycline in the metastatic setting; or,  in the adjuvant setting if 
recurrence occurred within [ADDRESS_1253570] had prior treatme n t  w i t h  a  H e r 2  
inhibitor (e.g. traztuzumab or lapatinib)
c. Patients who have received prio r taxane therapy may be enroll ed.  
8. Patients with thymic carcinoma mu st also meet the following cr iteria:
a.Must have received at least one prior systemic chemotherapy reg imen for metastatic, 
recurrent, locally advanced, or otherwise unresectable disease.
9.Â•\HDUVRIDJH
10. Measurable disease as defined by [CONTACT_786401] (RECIST 1.1, 
see Section 9)**
11. ECOG performance Status 0 or 1 (Section 15)12. Male or female patients of child-producing potential must ag ree to use contraception or 
avoidance of pregnancy measures during the study and for [ADDRESS_1253571]
14. Aspartate transaminase (AST) and alanine transaminase (ALT) d2.5 Ã— upper limit of normal 
(ULN),RUÂ” 3.5 Ã— ULN with metastatic liver disease.
15. Hemoglobin +JEÂ• 9g / d l
16. Total bilirubin d1.5 Ã— ULN
17. Creatinine d1.[ADDRESS_1253572] or creatinine clearance > 60 mL/min/1.73 m
2for patients with 
creatinine levels above institutional normal.   
18. Absolute neutrophil count t1.5 x 109/L
19.3ODWHOHWVÂ•[9/L, patients with hepatocellular carcinoma (HCC) may enroll prov ided 
they have SODWHOHWVÂ•[9/L
20./LIHH[SHFWDQF\Â•PRQWKV
*Patients must have only one ma lignancy diagnosis at the time o f enrollment.  A history of curatively 
resected non-melanoma skin cancer or curatively treated cervica l carcinoma in situ is permitted.  A 
history of another primary solid  tumor is permitted provided th ere is no known active disease present 
and the investigator and medical monitor for the sponsor agree t hat the history will not affect patient 
outcome in the setting of the current malignancy.
**Patients may be enrolled provided disease can be objectively me asured using another disease-specific 
standard (e.g., tumor marker elevation).
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 163.[ADDRESS_1253573] been 
deemed irreversible, with the ex ception for a single dose radia tion up to 8 Gray (equal to 800 
RAD) with palliative intent for pain control up to [ADDRESS_1253574] 2 weeks prior to protocol 
enrollment. Patients with known l eptomeningeal metastases are e xcluded, even if treated.
4. Pregnant or breastfeeding 
5. Significant gastrointestinal disorder(s), in the opi[INVESTIGATOR_1101] t he Principal Investigator, (e.g., 
Crohnâ€™s disease, ulcerative co litis, extensive gastric and smal l intestine resection)  
6. Unable or unwilling to swallow BBI608 capsules daily    
7. Uncontrolled intercurrent illn ess including, but not limited to ongoing or active infection, 
clinically significant non-healing or healing wounds, symptomat ic congestive heart failure, 
unstable angina pectoris, cardiac arrhythmia, significant pulmo nary disease (shortness of 
breath at rest or mild exertion), uncontrolled infection or psy chiatric illness/social situations 
that would limit compliance with study requirements
8. Known severe hypersensitivity to paclitaxel
9. Abnormal ECGs (ie, QT prolongation â€“ QTc > 480 msec, signs of c ardiac enlargement or 
hypertrophy, bundle branch block, signs of ischemia or necrosis  and Wolff Parkinson White 
patterns)*
*Patients with abnormal ECG findings may enroll provided the fi ndings do not represent clinically 
significant heart disease, and provided there is agreement betwe en the principal investigator [INVESTIGATOR_894637]. 
3.[ADDRESS_1253575] number of patients estimated for this trial is depend ent on the number of patient cohorts 
investigated based on the toxic ity encountered.  In the phase 2  portion of the study up to 550additional 
patients may be enrolled. It is expected that up to approximately 570 patients will be enrolled for this 
study. Patient accrual will occur over a period of time dependen t upon the number of cohorts enrolled.
Under protocol amendment 3.0, only 10 to 15 patients with thymi c carcinoma may be enrolled.
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 174 INVESTIGATIONAL PLAN
4.1 Overall Study Design
This is an open-label, multicente r Phase Ib study of oral BBI608  administered with paclitaxel to patients 
with advanced malignancies. The s tudy is designed to explore th e safety, tolerability and 
pharmacokinetics of BBI608 and paclitaxel and define a recommen ded Phase 2 dose.
Treatment will be initiated at a dose level of 1000 mg total dai ly dose of BBI608 for BID regimen and 
escalate until the RP2D or MTD is determined. In each cycle, BBI 608 will be taken daily continuously 
for 4 weeks (28 days).  BBI608 will be administered daily one h our prior or two hours after meals with 
the first dose taken in the morning.  On day 3, 10, and 17 of ea ch 28 day cycle, patients will receive
paclitaxel at 80 mg/m2given as a [ADDRESS_1253576] morni ng dose of 
BBI608.
Cycles (28 days) will be repeated until progression of disease, u nacceptable toxicity, or another 
discontinuation criterion is met.  In the case of toxicity, adj ustment is permitted. 
Dose escalation will be perform ed using three-patient cohorts a s shown in the table below
Phase Ib Dose escalation scheme for BBI608 
CohortTotal Daily Dose   
(mg)Number of 
Patients
Ib [ADDRESS_1253577] cycle of therapy, an additional three 
patients will be enrolled at the same dose level.  
The MTD is defined as the dose le vel at which no more than one patient with DLT is observed among 
six patients.  If MTD is not reached, the recommended Phase 2 do se (RP2D) of BBI608 will be
determined by [CONTACT_894663] a dose level w hich gives the best exposure.
Phase Ib will end when there are < 2 patients with DLT out of 6  evaluated for DLT at the regimen 
selected for use as RP2D.
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 18Number of Subjects with 
DLT at a Given Dose LevelEscalation Decision Rule
0 out of 3 Enter 3 subjects at the next dose level
>2Dose escalation will be stopped.  This dose level will be 
declared the maximally administered dose (highest dose administered).  Three (3) additional subjects will be entered at the next lower dose level if only [ADDRESS_1253578] 3 more subjects at this dose level.
xIf 0 of these 3 subjects experience DLT, proceed to the 
next dose level.
xIf 1 or more of this group suffer DLT, then dose 
escalation is stopped, and this dose is declared the 
maximally administered dose.  Three (3) additional 
subjects will be entered at the next lower dose level if only 3 subjects were treated previously at that dose.
<[ADDRESS_1253579] dose level 
below the maximally administered doseThis is the recommended phase 2 dose.  
4.2 Rationale for Study Design 
Considerable data has been col lected from the Phase I monothera py study of BBI608 (Protocol BBI608-
101) conducted in advanced oncolo gy patients who have failed mu ltiple previous regimens.  Dose 
escalation for BBI608 has been s uccessfully conducted from a tot al daily dose of [ADDRESS_1253580] 
b e e n  g e n e r a l l y  m i l d  w i t h  t h e  m o s t common being: diarrhea, nause a ,  a n d  f a t i g u e .   G r a d e  3  e v e n t s  
include: fatigue or diarrhea. No bone marrow suppression or neurop athy was observed.
In the BBI608-201 study, dose escalation of BBI608 will be begi n at a dose of 500 mg bid with a total 
daily dose of 1000 mg, in combination with 80 mg/m2of paclitaxel weekly. The starting dose of 
BBI608 will be at 600 mg (total daily dose) for tid regimen. The dose escalation schedule of BBI608 
is presented in Section 4.1.
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 194.[ADDRESS_1253581] been observed in the BBI608-101 phase I trial. 
BBI608 has been well tolerated in phase I trials. MTD was not r eached in the BBI608-101 Phase I study 
with doses escalated from 20 mg up to 1000 mg bid (2000 mg total daily dose). Further dose escalation
above 2000 mg/day is limited by [CONTACT_21173][INVESTIGATOR_13551]. 
Adverse events observed in the BBI608-[ADDRESS_1253582] 
common being: diarrhea, nausea, and fatigue.  Grade 3 events in clude: fatigue or diarrhea. There is no 
clinically significant overlap b etween adverse events observed for BBI608 and the adverse effects of 
paclitaxel. 
The sponsor believes that the p roposed study is acceptable in t he context of its risks and benefits.
4.[ADDRESS_1253583] 28 days of continuous daily 
administration of BBI608.   Based on the tolerability and safet y of evaluable patients, enrollment at the 
next dose level and/or additiona l patients into the ongoing coh ort will occur according to criteria 
described below: 
xIf zero treated patients experience a DLT (defined below) by [CONTACT_140969] y 28, then dose escalation will 
occur.
xIf one treated patient experiences a DLT by [CONTACT_2006] 28, then an add itional three patients will be 
enrolled for a total of six patients treated at the same dose l evel.  Escalation will occur if no 
additional DLTs are seen in that cohort (one out of six patient s) 
xIf two or more treated patients at a dose level experience a DL T by [CONTACT_2006] 28, dose escalation 
will stop and this dose level w ill be considered the maximally administered dose.
The BBI medical Monitor and Principal Investigator [INVESTIGATOR_894638] .  Intermediate doses may be assigned 
to a cohort after agreement betw een the BBI Medical Monitor and  the Principal Investigator. 
4.6 Dose-Limiting Toxicity
Dose-limiting toxicity is defined by [CONTACT_894664] t he following toxicities possibly or 
probably related to BBI608 within 28 days of treatment.  DLT wil l be scored during the 28 days of 
BBI608 treatment. 
xGrade 4 hematological toxicity
xGrade 3 or 4 non-hematol ogical toxicity, except: 
oGrade 3 or 4 nausea/vomiting/anorexia, diarrhea or fatigue will be  considered a DLT 
only if it persists more than three (3) days despi[INVESTIGATOR_894639] a DLT
Adverse events considered rela ted to paclitaxel will not be con sidered DLTs
4.7 Study Duration 
Patients will receive treatment with BBI608 and paclitaxel until progression of disease, unacceptable 
toxicity or another of the disc ontinuation criteria is document ed (see Section 5.6).  It is expected that
most patients will receive between one and four cycles of BBI60 8 and paclitaxel for a treatment period 
of four to 16 weeks. 
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: [ADDRESS_1253584] of a Pre-S tudy Evaluation, during which  the patient is evaluated to determine 
suitability for entry into the study; Cycle [ADDRESS_1253585] cycle only; Evaluations in Cycle 2 and beyond, which wi ll be performed in Week 1 of each 
cycle; and an End-of-Study Evalua tion. (See Section 14 for a sche dule of Assessments)
Following the Pre-Study Evaluation and a determination by a Pri ncipal Investigator that the patient 
meets all inclusion/exclusion cr iteria and signs the informed c onsent, the patient will be considered 
entered into the study.
5.1 Informed Consent
Patients who agree to participate will sign the approved inform ed consent and will be provided a copy 
of the signed document.  
5.2 Pre-Study Evaluations (Baseline) (up to 1 week Â±[ADDRESS_1253586] dose of 
BBI608*)
After written informed consent is obtained according to ICH-GCP  and local regulations, the patient 
will be evaluated for inclusion and exclusion criteria accordin g to the eligibility criteria listed in Section 
3.  
The following will be evaluated  and documented within seven day s prior to first dose of BBI608:
xMedical history
xPhysical examination
xECOG performance status  (see Section 15)
xVital signs (weight, temperature , blood pressure, height, respi [INVESTIGATOR_34403])
xHematology (see Section 6.3)
xBlood chemistry (see Section 6.3)
xLiver function tests (see Section 6.3)
xElectrolytes (see Section 6.3)
xUrinalysis (see Section 6.3)
xSerum pregnancy test (if applicable)
xTumor markers if applicable
xTumor biopsy, if applicable (see Section 6.5.1)
x12-lead electrocardiogram (ECG)
xTumor measurement and staging[co mputed tomography (CT) or magne tic resonance imaging 
(MRI) acceptable] *
*All CT and MRI scans can be used as the baseline assessment if  they were performed within 
three weeks prior to the first scheduled dose of BBI608.  
Archival tissue samples from a prior biopsy or surgery should b e collected from all patients enrolled in 
the clinical trial if they are available (See Section 17: Appen dix E).
5.3 On-Study Assessments
5.3.1 Cycle [IP_ADDRESS] Week 1 (Cycle 1, Day 1)
xDispense BBI608 (three day supply)
x12-lead electrocardiogram ([ADDRESS_1253587] BBI608 dose)
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 21xProvide instructions for patient to administer anti-diarrheal p re-medication [ADDRESS_1253588] dose of protocol therapy, provided there is n o medical contraindication (see 
section 7.2.2).
[IP_ADDRESS] Week 1 (Cycle 1, Day 3)
xECOG performance status 
xVital signs (weight, pulse)
xHematology (see Section 6.3)
xBlood chemistry (see Section 6.3)
xLiver function tests (see Section 6.3)
xElectrolytes (see Section 6.3)
xUrinalysis (see Section 6.3)
xAssess AEs
xRecord concomitant medication
xPaclitaxel IV infusi on over [ADDRESS_1253589] dose.
xDispense BBI608 (one week supply)
[IP_ADDRESS] Week 2 (Cycle 1, Day 10)
The following assessments w ill be made during this visit:
xECOG performance status 
xVital signs (weight, pulse)
xHematology (see Section 6.3)
xBlood chemistry (see Section 6.3)
xLiver function tests (see Section 6.3)
xElectrolytes (see Section 6.3)
xAssess AEs
xPaclitaxel IV infusion over [ADDRESS_1253590] morning dose of BBI608,
xDispense BBI608 (one week supply)
[IP_ADDRESS] Week 3 (Cycle 1, Day 16)
xThe second dose of BBI608 will be t aken approximately [ADDRESS_1253591] dose.  
xBlood samples for pharmacokine tics [select study sites only], ( see Section 6.4)
For patients enrolled at select study sites, blood samples for pharmacokinetics will be collected 
immediately prior to the first dose of BBI608 on Cycle [ADDRESS_1253592] dose of BBI608.  Spe cific details for the collection of blood 
samples for pharmacokinetics can  be located in Sections 6.4 and Section 16.
[IP_ADDRESS] Week 3 (Cycle 1, Day 17) 
The following assessments w ill be made during this visit:
xECOG performance status
xVital signs (weight, pulse)
xHematology (see Section 6.3)
xBlood chemistry (see Section 6.3)
xLiver function tests (see Section 6.3)
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 22xElectrolytes (see Section 6.3)
xUrinalysis (see Section 6.3)
xAssess AEs
xPaclitaxel IV infusion over [ADDRESS_1253593] dose.  
xBlood samples for pharmacokinetics [select study sites only], (D ay 17 of Cycle 1 only [see 
Section 6.4])
xDispense BBI608 (two week supply)
For patients enrolled at select study sites, blood samples for pharmacokinetics will be collected 
immediately prior to the first  dose of BBI608 and will continue through [ADDRESS_1253594] dose of BBI608.  Specific details for the collecti on of blood samples for pharmacokinetics 
can be located in Sections 6.4 and Section 16.
5.3.2 Monthly Evaluations (Cycle 2 and beyond)
[IP_ADDRESS] Week 1 (Day 3)
Patients will have the following assessments:
xPhysical examination 
xECOG performance status
xVital signs (weight, temperature , blood pressure, respi[INVESTIGATOR_1516] a nd pulse)
xHematology (see Section 6.3)
xBlood chemistry (see Section 6.3)
xLiver function tests (see Section 6.3)
xElectrolytes (see Section 6.3)
xUrinalysis (see Section 6.3)
xTumor markers, if applicable
xAssess adverse events (AE)
xRecord concomitant medication
xPaclitaxel IV infusion over [ADDRESS_1253595] morn ing dose of BBI608
xDispense BBI608 (28 day supply)
5.4 Tumor Evaluation Visits
Disease status and tumor respons e will be assessed in eight-wee k intervals up to one year after starting 
therapy (calculated from the first dose of BBI608) or as clinic ally indicated. Standard imaging studies 
should be performed according to institutional procedures. Tumo r response for solid tumors will be 
evaluated using the guidelines for Response Evaluation Criteria  in Solid Tumors (RECIST 1.1) outlined 
in Section 9.
Once progression of disease during therapy is documented, patie nts may receive any therapy as 
determined by [CONTACT_24018] (see Section 5.6).
A protocol radiologic assessment consists of computed tomograph y (CT) imaging of the chest, 
abdomen, and pelvis with IV contrast.  Non-contrast imaging is a llowed in patients with an allergic 
reaction to IV contrast material despi[INVESTIGATOR_894640], provided the tumor lesions 
can be measured and followed reproducibly, according to the inv estigator.  An alternate method for 
those with allergy to CT contrast  material is an MRI of the abd omen and pelvis and a non-contrast CT 
of the chest.  
Images should continue to be obt ained every 8 weeks (56 days) f rom the first dose of BBI608 until 
radiologic disease progression is documented. A window of Â± 7 d ays is allowed when scheduling scans.
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 23A confirmatory scan should be performed [ADDRESS_1253596]  observation of CR or PR.  After the 
confirmatory scan, imaging will continue every 8 weeks (56 Â± 7 days).  
De-identified digital copi[INVESTIGATOR_1309] r adiologic images may be reques ted for the purposes of exploratory 
review. 
5.[ADDRESS_1253597] resolved to basel ine 
(or < Common Terminology Criteria for Adverse Events [CTCAE] Gr ade 1), stabilized or are deemed 
irreversible.  
The following assessments will be  made during the end of study visit:
xPhysical examination
xECOG performance status 
xVital signs (weight, temperature , blood pressure, respi[INVESTIGATOR_1516] a nd pulse)
xHematology (see Section 6.3)
xBlood chemistry (see Section 6.3)
xLiver function tests (see Section 6.3)
xElectrolytes (see Section 6.3)
xUrinalysis (see Section 6.3)
x12-lead ECG
xTumor marker, if applicable
xTumor measurement and staging if  applicable for solid tumors an d lymphoma
xAssess adverse events
xRecord concomitant medications
5.6 Discontinuation from Study
Patients will be removed from th e study at any time if they mee t any of the following criteria:
xDocumented radiologic* or clin ical progression of disease
xNoncompliance with any part of the study, as evaluated by [CONTACT_941] P rincipal Investigator and 
Medical Monitor
xWithdrawal of consent
xLost to Follow-up
xDeath 
xClinically unacceptable toxiciti es despi[INVESTIGATOR_894641].
*Since BBI608 targets cancer stem cells, patients may continue protocol therapy or BBI608 alone 
beyond radiologic progression provided there is no clinical det erioration.
Patients will be followed for Overall Survival after discontinui ng protocol therapy. The follow-up
schedule is quarterly for the fi rst [ADDRESS_1253598] for the patient.    
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 246 STUDY PROCEDURES
6.1 Medical History
Medical history will include, but will not be limited to, the follo wing:
xDemography: date of birth, sex, ethnic origin, height, and weig ht
xClinically significant prior di agnoses, surgeries, and current medications
xPrior cancer history, current can cer diagnosis, tumor stage at time of diagnosis and screening, 
previous chemotherapy, including dates and duration of treatmen t, previous radiation therapy, 
including anatomic site, dose and date of treatment
6.2 Physical Examination
Complete physical examination incl uding height, weight, blood p ressure, heart rate, respi[INVESTIGATOR_697], 
temperature (oral, axillary or tympanic) and ECOG performance s tatus (Section 15).
6.[ADDRESS_1253599] be obtained at a  primary laboratory designated by [CONTACT_1268].  
xHematology: CBC including hemogl obin, hematocrit, white blood c ell count with 5-part 
differential, red blood cell, platelet.
xBlood chemistry: HCO 2, calcium, phosphorus, magnesium, albumin, glucose, and serum 
creatinine
xLiver function tests: AST, ALT, lactate dehydrogenase (LDH), al kaline phosphatase, total and 
direct bilirubin, uric acid, total protein and blood urea nitro gen (BUN)
xElectrolytes: sodium, potassium, and chloride 
xRoutine urinalysis: dipstick and microscopy including protein, specific gravity, glucose and 
blood
xSerum pregnancy test for female patients of childbearing potent ial
xPlasma tumor markers, which may i nclude exploratory markers, will be collected.
Cancer Type Tumor Marker
Ovarian Cancer CA-125
Gastric Cancer CEA, CA 19-9
Pancreatic Cancer CA 19-9
Hepatocellular  Carcinoma AFP
Prostate Cancer PSA
6.4 Pharmacokinetic Assessments 
Blood samples for the PK of BBI 608 and paclitaxel will be colle cted from patients enrolled at selected 
study sites.  Approximately 32 blood samples for PK will be coll ected for each patient.  Collection, 
storage, and shippi[INVESTIGATOR_894642] D.
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 256.[ADDRESS_1253600] tumor samples  will be processed for determina tion of pharmacodynamic markers in 
malignant tissue by [CONTACT_130149].
6.5.1 Tumor Biopsy
Patients who are identified by [CONTACT_079] [INVESTIGATOR_130136] a lesion, which could be biopsied 
with a minimally invasive procedure, will be asked to sign an a dditional consent.  Tumor samples 
should be collected at baseline and approximately 4 h after admi nistration of the BBI608 morning dose 
on Day 17. Collection, storage, and shippi[INVESTIGATOR_894643] l l  b e  p e r f o r m e d  a s  d e s c r i b e d  i n  
Appendix E.
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: [ADDRESS_1253601] Label ap proved by [CONTACT_130150] 
(see Appendix F ).
7.1.[ADDRESS_1253602] 
one cycle in other patient(s).  
xIntra-patient dose de-escalation is allowed provided that the n ew dose level is below MTD 
(maximum tolerated dose) and the  new dose level is agreed by [CONTACT_3433] e Principal Investigator [INVESTIGATOR_894644]. 
7.1.[ADDRESS_1253603] Labels a pproved by [CONTACT_67435] (see Appendix F ).
xPaclitaxel will be administered via IV at 80 mg/m2once weekly as a 1-hour infusion*, on Days
3, [ADDRESS_1253604] daily 
dose of BBI608.
*In the case of an adverse or infusion reaction to paclitaxel, the rate of administration  may be reduced according 
to institutional standards.
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 277.1.4 Body Surface Area Calculation
The calculation of the dose of p aclitaxel will be based on the p atientâ€™s body surface area (BSA)*.  The 
BSA will be calculated before each  cycle, based on the actual h eight and weight of the patient.  The 
calculated dose will be adjusted downward to the nearest whole milligram. 
*Mosteller method
7.[ADDRESS_1253605] dose of paclitaxel in a given cycle, the absol ute neutrophil coun t (ANC) must be t1.5
Ã— 109/L and the platelet count must be t100 Ã— 109/L.  If these parameters are not met, and in the opi[INVESTIGATOR_1649] 
o f  t h e  i n v e s t i g a t o r  t h e  m y e l o s u p p r e s s i o n  i s  m o s t  l i k e l y  a  r e s u l t of paclitaxel therapy, the dose of 
paclitaxel should be reduced according to the following criteria :
xFor ANC 0.5-1.49Ã—109/L or platelet count 50-99.0Ã—109/L, hold paclitaxel dose until recovery 
(ANC t1.5Ã—109/L and platelet count t100 Ã— 109/L) then recommence on the same schedule 
and dose. Neupogen/G-CSF may be u sed at the discretion of the p rincipal investigator.
xFor ANC <0.499Ã—109/L or platelet count <50.0 Ã— 109/L, hold paclitaxel dose until recovery 
(ANC t1.5 Ã—109/L and platelet count t100Ã—109/L) then recommence on the same schedule but 
reduce the dose level by 20%.
Prior to subsequent paclitaxel do ses in a given cycle, the abso lute neutrophil count (ANC) must be t1.0
Ã— 109/L and the platelet count must be t100 Ã— 109/L.  If these parameters are not met, and in the opi[INVESTIGATOR_1649] 
o f  t h e  i n v e s t i g a t o r  t h e  m y e l o s u p p r e s s i o n  i s  m o s t  l i k e l y a  r e s u l t  of paclitaxel therapy, the dose of 
paclitaxel should be reduced according to the following criteri a:
xFor ANC 0.5-0.99Ã—109/L or platelet count 50-99.0Ã—109/L, hold paclitaxel dose until recovery 
(ANC t1.0Ã—109/L and platelet count t100 Ã— 109/L) then recommence on the same schedule 
and dose. Neupogen/G-CSF may be used at the discretion of the p rincipal investigator.
xFor ANC <0.499Ã—109/L or platelet count <50.0 Ã— 109/L, hold paclitaxel dose until recovery 
(ANC t1.5 Ã—109/L if the first of a cycl HRWKHUZLVH$1&Â•Ã® 109/L; and platelet count 
t100Ã—109/L) then recommence on the same schedule but reduce the dose le vel by 20%.
If a dose of paclitaxel is held, it may be administered on an al ternate week upon count recovery such 
that weekly administration of p aclitaxel for [ADDRESS_1253606] lik ely a result of paclitaxel the rapy, the dose of paclitaxel should be 
reduced by 20% for subsequent doses of paclitaxel.
7.2.1 Additional Recommendations
The above are considered minim um guidelines.  The paclitaxel do se may be adjusted by [CONTACT_894665] o ther than those specifically me ntioned above.  
In addition, if a toxicity has occurred for either BBI608 or pac litaxel, subsequent dosing may be delayed 
up to two weeks with the following conditions: 
xIf the toxicity resolves WRÂ”J rade 2 or to the baseline grade, dosing may resume at the curre nt 
dose level.
xIf criteria for treatment are still not met, the patient may be  removed from the protocol.
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 28Patients should continue to be treated using the same dosing re gimen prescribed for the cohort in which 
they were originally enrolled.  I f breaks in treatment are requ ired the following guidelines should be 
used:
xPatients experiencing an AE or po tential DLT should resume trea tment, if possible, using 
an alternative-dosing schedule (to be discussed with the Sponso r medical monitor).
Patients who cannot tolerate their assigned dose after trying a n alternative schedule should be 
replaced if they have not complete d their first cycle (and are therefore not evaluable for 
determination of dose escalation).
For any BBI608-related intolerabl e grade 3 or intolerable grade  2 adverse event, persisting despi[INVESTIGATOR_894645], a dose holiday of 1-3 days follow ed by [CONTACT_894666]. Dose modification may include reduction of the tot al daily dose and/or in the number 
of doses taken per day.  Investigators should discuss dose modi fications with the medical monitor for 
the sponsor.  Patients may up-titrate dose to full dose as tole rated.
If a toxicity is thought by [CONTACT_894667]608 and paclitaxel, then the dose 
modification rules for both agents should be followed.
7.2.2 Supportive Pharmacology
Pharmacologic agents that are commonly prescribed for the manag ement of adverse events associated 
with anti-cancer therapy are listed in Table 1.
Table 1: Supportive Pharmacology*
Diarrhea & Abdom inal Crampi[INVESTIGATOR_894646], Vomiting, or Anorexia1 
   
Dicyclomine  (e.g., Bentyl) : Recommended when the 
predominant issue is cra mpi[INVESTIGATOR_67401]   
1st line:  5HT3-inhibitors (Ondansetron, 
Palonosetron, Granisetron)  
Diphenoxylate/atropi[INVESTIGATOR_050] (Lomotil)  
 
Loperamide (Imodium)  These agents may 
be particularly useful in combination  
2nd line:   Dexamethasone  (Decadron) , ideally 
in combination with a 5HT3-inhibitor.   Short 
term use can be very effective 
Hyoscine (Buscopan, Scopo lamine, Levsin) :  Anti-
spasmodic agents helpful for abdominal crampi[INVESTIGATOR_210214] :  NK antagonist (e.g. 
Aprepi[INVESTIGATOR_053]), atypi[INVESTIGATOR_67128] (e.g. 
olanzapi[INVESTIGATOR_050]), benzodiazepi[INVESTIGATOR_1651] (e.g. 
lorazepam), phenothiazines (e.g. 
prochlorperazine), cannabinoids (e.g. dronabinol), and other agents such as 
metoclopramide or scopolamine.  
Corticosteroid with limit ed systemic absorption2   
1Adapted from NCCN anti-emetic guideline 2017. 
2Alimentary tract mucositis refle cts mucosal injury across the c ontinuum of oral and gastrointestinal mucosal. 
Expert opi[INVESTIGATOR_1649] (2016 ESMO clinic al practice guideline recommend ations include systemic steroid treatment for 
the management of adverse event observed with the use of target ed agents. 
*Decisions on ADR management are at the discretion  of the inves tigator and must adhere with local regulatory 
guidelines.  
Anti-diarrheal pre-medication ad ministered [ADDRESS_1253607] dose of protocol therapy is 
recommended provided there is no medical contraindication. 
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 29Anti-emetic pre-medication is also recommended approximately on e hour prior to the first dose of 
protocol therapy if the patient  is not already on an anti-emeti c regimen and provided there is no medical 
contraindication. 
Recommendations for pre-medicatio ns are presented in Table 2 bel ow.
Table 2: Pre-Medication Recommendations
Category Specific Measures Start End
Anti-DiarrhealLoperamide 4 mg BID
orDiphenoxylate/Atropi[INVESTIGATOR_050] 
[ADDRESS_1253608] dose of BBI608
on Cycle 1, Day 1 Stop anti-diarrheal  if there are no 
bowel movements by [CONTACT_894668] 1, Day 3.
Can be continued and/or modified at 
the discretion of the treating 
investigator
Anti-EmeticOndansetron 8 mg once
or
Other anti-emetic  (5HT3-
antagonist preferred)Approx. [ADDRESS_1253609] dose of 
BBI608 on Cycle 1, Day 1May be continued and/or modified at 
discretion of treating investigator
7.3 Treatment Compliance
A patient is considered complia nt with the study protocol when study medication is administered at a 
compliance level of greater than 80%.  
BBI608 compliance will be calcula ted using the following equati on:
(Number of capsules actually ing ested /number of capsules that should have been ingested per dose 
level) x 100= % compliance
Paclitaxel compliance will be calculated using the following eq uation:
(Number of infusions performed /num ber of infusions that should ha ve been performed per dose level) 
x 100= % compliance
7.[ADDRESS_1253610] be recorded on the appropriate 
patient's case report form (CRF).  All surgical procedure histo ry, prior chemotherapy and radiation 
therapy must be recorded  on the appropriate CRF.
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 307.6 Concomitant Medication
7.6.1 Permitted Treatment
All information regarding concom itant treatments (medications o r procedures) must be recorded on the 
patientâ€™s CRF (including the nam e of the medication or procedur e and duration of treatment). 
Palliative and supportive care for disease-related symptoms wil l be offered to all patients in this study.  
Patients may receive palliative radiation therapy. 
In addition, the following treatments are allowed:
xStandard therapi[INVESTIGATOR_53301] c oncurrent medical conditions
xEpoetin alfa (EpogenÂ®, ProcritÂ®)
xHematopoietic growth factors,  including filgrastim (NeupogenÂ®), or other granulocyte colony 
stimulating factors (G-CSF), are permitted following documented  and clinically significant 
neutropenia after the patient has completed at least one cycle of treatment with 
BBI608
xProphylactic antiemetics may be a dministered according to stand ard practice 
xMegestrol acetate (MegaceÂ®)
xDethamethasone
xDiphenhydramine
xCimetidine
xRanitidine
7.6.2 Prohibited Treatment
xAny concurrent chemotherapy, non -palliative radiotherapy, hormon al therapy, or 
immunotherapy
xOther investigational agents
xImmunosuppressive therapi[INVESTIGATOR_014], incl uding systemic corticosteroids  (except when used 
intermittently in an antiemetic regimen or when prescribed at a  non-immunosuppressive dose 
for treatment of fatigue and l ow-appetite, or as a premedicatio n for paclitaxel infusion)
7.6.[ADDRESS_1253611] been identif ied in patients administered BBI608,
although a dedicated drug interaction study is currently ongoing in healthy human volunteers.
Napabucasin is primarily metabo lized by [CONTACT_2750] P450 isoform 1A 2.  Therefore, caution should be 
exercised with drugs that are strong inhibitors or sensitive su bstrates of CYP1A2. 
Examples of strong 1A2 inhibitors and sensitive inducers are pr esented below:
xStrong CYP 1A2 inhibitors: fluvoxamine, ciprofloxacin, enoxacin , zafirlukast
xSensitive CYP1A2 substrates: alo setron, caffeine, duloxetine, m elatonin, ramelteon, 
tasimelteon, theophylline, tizanidine 
Possible actions for investigators with patients taking medicat ions as above include: discontinuing the 
medication entirely, continuing t he medication and monitoring f or adverse effects, and continuing the 
medication at a reduced dose and monitoring for adverse effects .   
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: [ADDRESS_1253612] enrolled in the study.  All 
AEs considered to be related to BBI608 occurring after any admi nistration of the study drug will be 
followed until the event resolves.  AEs will be evaluated using  the National Cancer Institute (NCI) 
CTCAE, Version 4.0, published [ADDRESS_1253613]-tr eatment follow-up period (21 Code of 
Federal Regulations [CFR] Â§312.64 [b]) on designated CRF pages.  AEs occurring following the 
signature [CONTACT_28513], but prior to the first dose of study drug will not be reported as AEs.  
It is also important to record all AEs that result in permanent  discontinuation of the investigational 
product being studied, whether serious or non-serious.
Serious adverse events (SAEs), a s defined below, must be report ed to [LOCATION_011] Biomedical Inc. or its 
representative within [ADDRESS_1253614] a causal relationship with 
the treatment.  An AE can there fore be any unfavorable and unin tended sign (including an abnormal 
laboratory finding, for example),  symptom, or disease temporall y associated with the use of a medicinal 
product, whether or not considere d related to the medicinal pro duct.
Laboratory data are to be collected as stipulated in this proto col, and toxicity trends will be analyzed 
utilizing objective toxicity criteria.  Clinical syndromes asso ciated with laboratory abnormalities are to 
be recorded as appropriate (e.g. , diabetes mellitus instead of hyperglycemia).  
Progression of disease is conside red an efficacy outcome parame ter and should not be captured as an 
AE.  A non-serious AE is any untoward medical occurrence that d oes not meet any of the criteria for 
SAEs as defined below.
Patients should be instructed to  report any AE that they experi ence to the investigator.  Investigators 
should assess the patient for AEs at each visit.  AEs occurring  during the clinical trial and the follow-
up period should be recorded on the appropriate AE CRF.  To cap ture the most potentially relevant 
safety information during a clinical trial, it is important tha t investigators record accurate AE terms on 
CRFs.
Wherever possible, a specific disease or syndrome rather than i ndividual associated signs and 
symptoms should be identified by [CONTACT_67442].  However, if an observed 
or reported sign or symptom is not considered a component of a specific disease or syndrome by [CONTACT_1275], it should be recorded as a separate AE on the CRF.
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 328.2 Serious Adverse Events
8.2.1 Definitions 
A serious adverse event (SAE) is  any adverse experience occurri ng at any dose that results in any of 
the following outcomes:
xDeath
xA life-threatening adverse drug experience
xInpatient hospi[INVESTIGATOR_331325], except for events that are 
clearly disease related 
xA persistent or significant disability/incapacity
xA congenital anomaly/birth defect
Important medical events may be  considered an SAE based upon ap propriate medical judgment.  
Under this protocol, scheduled hospi[INVESTIGATOR_894647].  Prolongation of a schedul ed hospi[INVESTIGATOR_894648].  Complications 
associated with scheduled pro cedures are considered an AE.
8.2.[ADDRESS_1253615] be reported to the Sp onsor immediately (not to exceed 24 
hours) by [CONTACT_130153].  The reaction must be complet ely described on the CRF and SAE 
report form.
Primary Medical Monitor Contact [CONTACT_3031]:
Matthew J. Hitron, MD
[LOCATION_011] Biomedical, Inc
[ADDRESS_1253616]
Cambridge, MA [ZIP_CODE], [LOCATION_003]
Telephone:[PHONE_18554] ext 8563
Fax: [PHONE_18555]
Emer gency Number :  1-508-410-5512Matthew J. Hitron , MD
:[PHONE_18556]  ext 8563
[PHONE_18557]
[PHONE_18558]
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 339 ASSESSMENT OF ANTI-TUMOR ACTIVITY IN SOLID TUMORS
The following definitions and cr iteria (from Response Evaluatio n Criteria in Solid Tumors [RECIST 
1.1, Eisenhauer et al. 2009]1) should be used for the baseline evaluations of existing disea se, and for 
the ongoing evaluation of tumor responses.
Measurable disease - the presence of at least one measurable lesion. 
Measurable lesions - lesions that can be accurately measured in at least one dimens ion with longest 
diameter t10 mm using conventional techniques or t10 mm with spi[INVESTIGATOR_25457]. Malignant lymph 
nodes must be t15 mm in the shortest diameter.
Non-measurable lesions - all other lesions, including sma ll lesions (longest diameter < 10 mm with 
conventional techniques, <[ADDRESS_1253617] scan or t10 mm to <15 mm in short axis), i.e., bone 
lesions, ascites, pleural/pericardial effusion, cystic lesions and also abdominal masses that are not 
confirmed and followed by [CONTACT_15218].
xAll measurements should be taken  and recorded in metric notatio n, using a ruler or 
calipers.
xThe same method of assessment and  the same technique should be used to characterize 
each identified and reported lesion at baseline and during foll ow-up.
xLesions will only be considered m easurable when they are superf icial (e.g., skin 
nodules and palpable lymph nodes).  For the case of skin lesion s, documentation by 
[CONTACT_6775], and a measurement with a ruler to estimate t he size of the lesion, 
is recommended.
9.[ADDRESS_1253618] should 
be performed using a 5 mm con tiguous reconstruction algorithm.
xAll imaging methods should be pe rformed according to institutio nal standards with 
each patient having consistency of methods beginning from basel ine through the 
course of the study.
9.2 Baseline Documentation of â€œTar getâ€ and â€œNon-Targetâ€ Lesions
xAll measurable lesions up to a maximum of five lesions total wi th a maximum of 2 
lesions per organ, representative of all involved organs should be identified as target 
lesions and recorded and measured at baseline*.
xTarget lesions should be selected on the basis of their size (l esions with the longest 
diameter) and their suitability  for accurate repeated measureme nts (either by [CONTACT_894669]).
xA sum of the longest diameter (LD) for all target lesions will be calculated and reported 
as the baseline sum LD.  The baseline sum LD will be used as th e reference by [CONTACT_349126]. 
xAll other lesions (or sites of disease) should be identified as  non-target lesions and 
should also be recorded at baseline.  Measurements of these les ions are not required, 
but the presence or absence of each should be noted throughout follow-up.
*In most circumstances, a radiology report alone is not sufficient for the purposes of documenting 
target lesion measurements at baseline.  The baseline images and images from each subsequent 
time point should be reviewed specifically according to RECIST 1.1 guidelines.  
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 349.3 Response Criteria
Evaluation of tar get lesions
Complete Response (CR): Disapp earance of all target lesions
Any pathological lymph nodes must have reduction in short axis of <10mm
Partial Response (PR): At least a 30% decrease in the sum of the  LD of target lesions, 
takin g as reference the baseline sum LD
Progressive Disease (PD): At leas t a 20% increase in the sum of the LD of target lesions, 
t a ki ng  a s  re fe r e nc e  t he  s m a l l e s t  s um  L D re c or de d s i nc e  t he  treatment started.  In addition t o the increase of 20%, the sum  
must also demonstrate an absolute increase of at least 5mm.   
The appearance of one or more new lesions is also considered 
pro
gression
Stable Disease (SD): Neither sufficient shrinkage to qualify for  PR nor sufficient 
increase to qualify for PD, taking as reference the smallest su m 
LD since the treatment started
Evaluation of non-tar get lesions
Complete Response (CR): Disappearance of all non-target lesions and normalization of 
tumor marker level.  All lymph nodes must be non-
patholo gical in size (<10mm short axis)
Stable Disease (SD): Persistence of  o n e  o r  m o r e  n o n - t a r g e t  l e s i o n(s) and/or 
maintenance of tumor marker level above normal limits
Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal 
progression of existin g non-tar get lesions*
*Confirmation imaging a minimum of [ADDRESS_1253619] response recorded from th e start of the treatment until disease 
progression/recurrence and is determined as indicated in the ta ble below:
Target 
lesionsNon-Target lesions Evaluation of 
New lesionsOverall response
CR CR No CR
CR Non-CR/non-PD No PR
CR not evaluated No PR
PR Non-PD or not all evaluated No PR
SD Non-PD or not all evaluated No SD
PD An y Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: [ADDRESS_1253620] primarily of summary displays (i.e., descriptive statis tics and graphs).  
10.2 Determination of Sample Size
Phase Ib
The sample size for this study was determined by [CONTACT_894670].  With 
cohort sizes of three to six patients, if the true underlying r ates of DLT are 0.1, 0.2, 0.3, 0.4, and 0.5, 
there will be 91%, 71%, 49%, 31%, and 17% chances, respectively , of escalating to the next full doses.
Phase II
There is no statistical hypothesis testing in the Phase II part  and the planned sample size of Phase II (20 
â€“ 40 per cohort) is considered to be clinically adequate to asse ss tolerability, safety, and preliminary 
anti-cancer activity of study drugs of interest, and actual sam ple size depends on the actual enrollment 
in each arm.
Sample Size Justification for Thymic Carcinoma Cohort:
A total of 10 (minimum) to 15 (m aximum) patients will be target e d t o t hi s  c o hor t  a nd  a  B a ye s i an 
posterior probability approach will be employed to monitor the enrollment based on the overall 
response rate (ORR) by [CONTACT_10585] 16. A fter the first 10 patients hav e response evaluation, or withdraw, or 
die by [CONTACT_10585] 16, the Bayesian posterior probability of the ORR b eing greater than a target value will 
be continuously evaluated. If the  posterior probability is grea ter than 70% or less than 20%, then further 
enrollment may be stopped. Otherwise enrollment will continue un til the enrollment cap of [ADDRESS_1253621] the  mean equal to the historically 
observed ORR of 0.22 (Lemma 2011).
10.[ADDRESS_1253622] one disease 
assessment following the initiation of therapy will be consider ed evaluable for response.  The 
anti-tumor activity will be evaluated on an exploratory basis a nd will be summarized  using descriptive 
statistics or graphics.
For each tumor type, the following endpoints will be summarized : Objective response rate (ORR), 
defined as the proportion of pati ents with a documented complet e response (CR) or partial response 
(PR) based on RECIST 1.1; Disease Control Rate (DCR), defined a s the proportion of patients with 
documented CR, PR and stable disease (SD) based on RECIST 1.1; progression free survival (PFS),
defined as the time from enrollment until the first objective o bservation of disease progression or death 
from any cause; and overall survival (OS), defined as the time from enrollment until death from any 
cause.
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 3610.4 Demographics and Baseline Characteristics
Patient characteristics will include a complete summary of the following and will be recorded in the 
CRFs:
xPatient demographics
xBaseline disease characteristics
xPre-existing conditions
xPrior therapi[INVESTIGATOR_894649] w ill be summarized as appropriate .
10.[ADDRESS_1253623] deviation, coefficient o f variation, minimum, maximum,  and median .
Concentration profiles will be a nalyzed by [CONTACT_130155] /or nonlinear least squares regression 
using WinNonLin.  Pharmacokine tic parameters, including C max, volume of distribution, distribution 
half-life, terminal half-lif e, and AUC will be evaluated. 
10.[ADDRESS_1253624] dose of BBI608, or u ntil recovered from all related BBI608
adverse events. 
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: [ADDRESS_1253625] (for 
whom the deviation from the protocol was affected) is to contin ue in the study.  The case records will 
describe the deviation from the protocol and state the grounds for it.
11.[ADDRESS_1253626] dose of study drug.  
Registration and enrollment for ms and faxing instructions will b e provided with the case report forms 
(CRFs).  The site should maintain a log of all subjects who are  screened but do not qualify for the study 
or who do not receive study drug .  The reason for disqualificat ion should be noted in the log.
11.[ADDRESS_1253627].
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: [ADDRESS_1253628] be approved by [CONTACT_3786]â€™s IRB or Independent Ethics committee (IEC) (compl iant with federal regulations 
21 CFR 56) before the study is initiated.  Documentation of thi s approval (i.e., a copy of the 
document showing IRB/IEC approva l including the chairpersonâ€™s s ignature and the date of 
approval) must be provided to [LOCATION_011] Biomedical or its designee , and made available during 
an inspection by [CONTACT_1622], Health Canada or other regulatory age ncy inspectors.  The 
Investigator will submit to [LOCATION_011] Biomedical:
- A list of the names, occupatio ns, and affiliations of the memb ers of the IRB
- Documentation that the IRB is duly constituted or a General As surance Number
- No supplies will be shipped until the IRB has given written ap proval of the protocol 
and informed consent and [LOCATION_011] Biomedical has received copi[INVESTIGATOR_894650]:
- Submit to the IRB/IEC for review any advertisements that will be used to recruit 
subjects
- During the conduct of the st udy, submit progress reports to th e IRB, if required, and 
request review of the study 
- Report, in writing, to the IRB all SAEs that occurred during t he study or SAEs reported 
in other studies using study drug, per local IRB regulations
- Inform the IRB of any changes in the protocol and obtain docum ented IRB approval 
of the changes
- Maintain a file of study-related information, including all co rrespondence with the 
IRB/IEC
- Within [ADDRESS_1253629] be conducted in compliance with IRB/IEC informe d consent regulation and 
the ICH GCP Guidelines.  In addition, all local regulatory requ irements will be adhered to, in 
particular those which afford greater protection to the safety of the trial participants.
This study will be conducted according to the current revision of the Declaration of Helsinki 
(Revised Edinburgh, Scotland, 2000) and with local laws and reg ulations relevant to the use of 
new therapeutic agents in the country of conduct.
Before initiating a trial, the I nvestigator/institution should have written and dated 
approval/favorable opi[INVESTIGATOR_5698]/IEC for the trial proto col/amendment(s), written 
informed consent form, patient recruitment procedures (e.g., ad vertisements) and written 
information to be provided to patients.
Changes to the protocol will require written IRB/IEC approval/f avorable opi[INVESTIGATOR_146949], except when the modification is needed to elimi nate an immediate hazard(s) 
to patients.
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 3912.[ADDRESS_1253630] 
obtain informed consent from each study participant (or the sub jectâ€™s parent/guardian) in 
accordance with the US federal regulations (21 CFR Part 50) and  ICH document â€œGuidance 
for Industry â€“ E6 Good Clinical P ractice: Consolidated Guidanceâ€  dated April 1996.  It should 
also include any additional info rmation required by [CONTACT_8522].
Informed consent must be obtaine d from the subject before any s creening activity, washout of 
medication, or treatment (that is not part of routine care) is undertaken.  Informed consent will 
be obtained by [CONTACT_894671] s tudy, the risks and benefits, the 
study procedures, and any other in formation relevant to the sub jects.
The subject or his/her legal representative will document their  informed consent by [CONTACT_894672], IRB -approved, informed consent f orm in the presence of a 
witness.
The person, who conducted the informed consent discussion with the subject and/or guardian, 
must also sign the informed consent form.  The subject should b e given a copy of the informed 
consent form with all of t he appropriate signatures.
The Principal Investigator [INVESTIGATOR_67416] a copy of the signe d consent is kept with the Clinical 
Trial Master File.
The Investigator or designee must explain to the patient subjec t that for evaluation of study 
results, that subjectâ€™s private  health information obtained dur ing the study may be shared with 
the study Sponsor, regulatory agencies, and ECs/IRBs, before en rolling that subject into the 
study. It is the Investigatorâ€™s (or designeeâ€™s) responsibility to obtain permission to use private 
health information per HIPAA from each subject, or if appropria te, the subjectâ€™s parent or legal 
guardian.
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: [ADDRESS_1253631] 
be obtained before the modificati ons are implemented.  [LOCATION_011] B iomedical will submit protocol 
modifications the FDA, and to Health Canada.
13.2 Investigator Brochure and Information Materials
Before the study begins, the I nvestigator will receive an Inves tigatorâ€™s Brochure describing all 
known contraindications, warnin gs, precautions, and adverse rea ctions associated with the 
administration of the study drug.   If such information is revis ed while the study is in progress, 
the brochure will be amended or revised, and [LOCATION_011] Biomedical will provide the most current 
version to the Investigator.
13.3 Pre-investigational Documents
Prior to the shipment of the study drug(s), the Investigator wi ll supply [LOCATION_011] Biomedical with 
the following:
- A signed Investigator Clinical Research Agreement
- A completed Form FDA [ADDRESS_1253632] of the IRB members (lis ted on Form FDA 1572) and the mem ber occupations 
and affiliations; written verifica tion that the IRB is duly con stituted or the General 
Assurance Number
13.[ADDRESS_1253633]
The Investigator, or a responsible party (research pharmacist o r other) designated by [CONTACT_3786], must maintain an inventory record of drug receive d and dispensed.  [LOCATION_011] 
Biomedical will provide forms to  facilitate the inventory contr ol.  These forms must be used 
unless the Investigator has previ ously established a system tha t complies with FDA and/or 
Health Canada regulations and is approved by [CONTACT_67456].   The study drug must be 
dispensed only to the instituti ons(s) specified on form FDA 157 2.
13.5 Disposition of Used and Unused Study Drug
Upon completion or termination of the study and after inventory  by a [LOCATION_011] Biomedical 
monitor or designated representa tive, all unopened drug is to b e returned to [LOCATION_011] Biomedical 
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 41in the original containers.  All used vials will be retained un til released for destruction by [CONTACT_894673]. Unopened returned drug, with complet ed [LOCATION_011] Biomedical 
forms for return shipment, should be shipped as instructed by t he Sponsor.
13.[ADDRESS_1253634] the data specified fo r each individual, and other fo rms as necessary.
The Investigator and/or institutio n is required to prepare and maintain these forms in 
accordance with federal regulatio ns (set forth in the Statement of Investigator Form FDA-1572)
and to sign, date, and return them to the Sponsor.
Upon the request of authorized [LOCATION_011] Biomedical or appropriate  regulatory agency personnel, 
the Investigator will make available for inspection subject sou rce documents, e.g., records of 
each subject who participates in this study.  This information will be treated as confidential.
13.[ADDRESS_1253635] be maintained for 25 years:
If the Investigator leaves the i nstitution where the study was conducted, he/she agrees that the 
records will be retained and will not be destroyed without prio r notification of [LOCATION_011] 
Biomedical.
[LOCATION_011] Biomedical will notify the Investigator when records are  no longer required.
13.[ADDRESS_1253636]â€™s initials and 
subject number.  The identity of an individual subject may not b e disclosed in any publication 
relating to this study.
In connection with this study, representatives of Health Canada , or other regulatory bodies 
outside of Canada, such as the  [LOCATION_002] Food and Drug Admi nistration representatives of 
the local IRB may, in certain circumstances, review study sourc e documentation including 
subject medical records.
13.[ADDRESS_1253637] medical records.
The status of drug storage, dispensing, and accountability will  also be assessed during periodic 
visits.
At any time, each site may be audited either by [CONTACT_67453], or by a contractor 
acting on behalf of [LOCATION_011] Biomedical, or by a regulatory agenc y such as the FDA or Health 
Canada.
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 4213.10 Case Report Form (CRF) Completion
A set of CRFs will be provided for each study subject.  All for ms must be filled out in non-
erasable ink or type d*.  The Investigator  will sign and date ea ch CRF as indicated.  Correction 
of data on a CRF will be made by [CONTACT_130162] a in a manner that leaves the 
previous entry legible and writing the correct information next  to the crossed out entry.  â€œWhite-
outâ€ and erasures are not permitted.  Each correction must be i nitialed and dated by [CONTACT_264775].  After the CRFs have been col lected by [CONTACT_67456], 
all corrections will be made via a query resolution form, and n o further corrections should be 
made on the siteâ€™s copy of the CRF.
*electronic CRFs (eCRFs) may also be provided that are [ADDRESS_1253638]â€™s completion of the study.  
A copy of this final report must a lso be provided to [LOCATION_011] Bio medical.
13.[ADDRESS_1253639] listing for cross-referencing.
The Investigator understands that the information developed in the clinical study will be used 
by [CONTACT_894674].  This information 
may be disclosed to other clini cal investigators, the FDA, Heal th Canada and other government 
agencies.
All information disclosed to t he Investigator(s) by [CONTACT_894675](s) conduct the clinical trial described in thi s protocol or generated by [CONTACT_3786](s) as results in the clinical trial shall be treat ed by [CONTACT_737](s) as strictly 
confidential.  The Investigato r(s) shall not use such informati on other than for the purpose of 
conducting the clinical trial and may not disclose such informa tion to others, except when such 
disclosure is to colleagues and/or employees who reasonably req uire the information to assist 
in carrying out the clinical tri al and who are bound by [CONTACT_894676].  
Notwithstanding, the Investigator(s) may use or disclose to oth ers any information which: (i) 
was known to the Investigator(s) prior to the date of its discl osure, (ii) is now, or becomes in 
the future, publicly available; or (iii) is lawfully disclosed to the Investigator(s) on a non-
confidential basis by a third party who is not obligated to Bos ton Biomedical or any other party 
to retain such information in confidence.
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 4313.14 Publication
[LOCATION_011] Biomedical acknowledges that the Investigator(s) have ce rtain professional 
responsibilities to report to the scientific community on findi ngs in clinical investigations they 
conduct.  The Principal Investigator [INVESTIGATOR_894651], provided such publication does n ot disclose any Confidential 
Information or trade secrets of [LOCATION_011] Biomedical (other than t he Clinical Data).  If the Study 
is conducted as part of a multi-center protocol, Principal Inve stigator agrees not to 
independently publish their findings except as part of an overa ll multi-center publication, unless 
specifically approved in writing by [CONTACT_67456]. The Princ ipal Investigator agrees to, 
prior to submitting a manuscript, abstract, or any other writte n or oral presentation describing 
the Data for publication or presentation, forward to [LOCATION_011] Bio medical a copy of the item to be 
submitted for publication or presentation.  Upon reasonable req uest by [CONTACT_894677] [ADDRESS_1253640] the right to require the  Principal Investigator [INVESTIGATOR_894652] (other than the Clinical 
Data) of [LOCATION_011] Biomedicalâ€™s a nd to require that any publicatio n or presentation concerning 
the Study acknowledge the Sponsorâ€™s support.
13.15 Research Outside the  Terms of this Protocol
[LOCATION_011] Biomedical has a legal responsibility to report fully to  the regulatory au thorities all the 
results of administration of  its investigational drugs.
No investigative procedures other than those described in this protocol shall be undertaken on 
subjects enrolled in this study (unless required for the care o f the subject), without the 
agreement of the IRB/Ethics Committee and [LOCATION_011] Biomedical.  T he nature and results of any 
such procedures must be recorded and reported by a method agree d between [LOCATION_011] 
Biomedical and the Investigator.  The consent of the subjects m ust be obtained before any such 
procedures are undertaken.
The investigative drug provided  to the Investigator for use und er this protocol may not be used 
for any other purpose, including  another study, compassionate u se, or personal use.
Confidential Page: 4414 APPENDIX A:  SCHEDULE OF ASSESSMENTS
* At selected study sites
1.       Calcula ted from the date of first BBI608 dose.   
2.       Refer to Section 6.[ADDRESS_1253641]/MRI has been p erformed within last three weeks .
7.       Unless CT/MRI has been p erformed within last four weeks.
8.       Patients will be follow ed until resolution of any drug-r elated AE or SAE occurring during  the study or w ithin [ADDRESS_1253642] categorization of progressive disease (if known).
10.Patients will be followed quarterly until the date of death.W e e k 0 2 [ZIP_CODE]
D a y 013 10 16 17 3 10 17Â•GD\VIURPODVW
BBI608 d oseÂ•GD\VIURPRII
stud y d ate
Window-10 to 0 
daysÂ± 7 days
Medi cal  hi s tory X
Physical examination XX X
Serum pregnancy 
test3 X
E COG performance 
status XX XXX X
Vital signs, Weight XX XXX X
Hematology2XX XXX X
Blood chemistry2XX XXX X
Liver function tests2XX XXX X
Electrolytes2XX XXX X
U rinalysis2XX XX X
12-Lead  
electrocardiogramXX X
Tumor markers3XX X
Tumor biopsy3XX X
Pharmacokinetics* XX
Tumor measurement 
& staging4,5 X6X7
Concomitant 
medicationsXX XXX X
Adv erse ev ents8XX X X X
Disp ense BBI 608 XXX X X
Paclitaxel infusion XX X XXX
Disease progression X9
Ov erall surv iv al X1013
Â± 1 day Â± 1 day
Scans will be performed at 8-week (56 day) intervals from Cycle  1, Day 1Tests & ProceduresPre-Study 
Eval uati onStudy Evaluations1
E nd of Stud y Visit Follow -up
Cycle 1 Cycle 2 & Beyond
Confidential Page: 4515 APPENDIX C:  PERFORMANCE STATUS
ECOG Performance status Scale Karnofsky Performance Scale
Grade Descriptions Percent Description
0Normal activity.  Fully active, able to 
carry on all pre-disease performance 
without restriction.100Normal, no complaints, no 
evidence of disease.
90Able to carry on normal 
activity; minor signs or 
symptoms of disease.
1Symptoms, but ambulatory.  Restricted in 
physically strenuous activity, but ambulatory and able to carry out work of 
a light or sedentary nature (e.g., light 
housework, office work).80Normal activity with 
effort; some signs or symptoms of disease.
70Cares for self, unable to 
carry on normal activity or 
to do active work.
2In bed <50% of the time.  Ambulatory 
and capable of all self -care, but unable to 
carry out any work act ivities.  Up and 
about more than 50% of waking hours.60Requires occasional 
assistance, but is able to care for most of his/her needs.
50Requires considerable 
assistance and frequent medical care.
3In bed >50% of the time.  Capable of only 
limited self-care, confined to bed or chair more than 50% of waking hours.40Disabled, requires special 
care and assistance.
30Severely disabled, 
hospi[INVESTIGATOR_374].  
Death not imminent.
4100% bedridden.  Completely disabled.  
Cannot carry on any self-care.  Totally 
confined to bed or chair.20Very sick, hospi[INVESTIGATOR_373]. Death not 
imminent.
10Moribund, fatal processes 
progressing rapi[INVESTIGATOR_375].
5 Dead. 0 Dead.
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 4616 APPENDIX D:  PHARMACOKINETIC STUDIES
Instructions for Coll ecting and Processing Samples
Sampling to define the plasma pharmacokinetics of BBI608 and pa clitaxel will be performed 
for patients enrolled at selected study sites.  Samples are tak en on Day [ADDRESS_1253643] be started before 10 a.m. on a Tuesday, Wednesday, or Thur sday to facilitate the 
collection of the pharmacokinetic samples at the scheduled time s during the re gular operating 
hours of the outpatient clinics.  
Before starting the BBI 608 administration, p lace a large gauge peripheral cathete r (e.g., 1 9 or 20 
gauge angiocath straight set w ith T-connector, or similar IV acc ess device) within a vein in the 
arm of the subject for the collection of pharmacokinetic blood samples.  Patency of the sampling 
catheter should be maintained between blood draws using either a heparin lock (e.g., 10 U/mL 
in normal saline) or a slow drip of Normal Saline for Injection , USP (e.g., 10 mL/hr).  
Extraordinary caution should be taken to prevent hemolysis in t he blood sample.  Blood may 
be obtained directly by [CONTACT_894678] a single  pharmacokinetic blood 
specimen is scheduled for coll ection.  When sam pling through th e peripheral catheter, begin to 
clear the catheter approximately 1  min before the specified sam ple time by [CONTACT_894679] 0.5 mL of blood into a syringe.   Remove and properly dispose 
the syringe used to clear the catheter.
A battery-powered digital timer/stopwatch programmed to operate continuously as a 24-hr 
clock will be used to accurately  monitor drug administration an d sample collection times.  The 
same timer must be allowed to r un without interr uption until th e last blood specimen has been 
obtained from the subject during the first cycle of therapy.  T imer readings will be noted at the 
precise time that the administration is started as well as at t he beginning and ending times of 
the blood sample collection inte rvals.  Readings of the digital  timer must be directly recorded 
on a copy of the appropriate Phar macokinetic Dosing and Blood C ollection Time Form.  
Please note that blood and plasma must be protected from direct  exposure to light and all 
sample processing procedures are to be performed in a room with  indirect lighting.  The volume 
of blood collected for each pharm acokinetic sample will be [ADDRESS_1253644] it on wet ice, and centrifuge (1,100-1,300 x g, 10 min, 4 Â°C) within 5-10 min after 
collection.  Separate the plasm a from the blood cells using a p ipette and transfer approximately 
equal volumes into three 2 mL sel f-standing opaque amber polypro pylene microcentrifuge 
cryogenic tubes with external thr eads. Affix a pre-printed label  (protocol number, subject 
initials, subject number, sampl e collection date and time) to t he cryotube, oriented lengthwise 
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 47toward the upper part of the tube. Hand-written information on s ample tube labels is absolutely 
prohibited. Completely cover the label with protective cryogenic  freezer tape.  Place the tube 
on crushed dry-ice until stored  in a freezer maintained at d-70Â°C.  Any deviation from the 
sample collection time needs to b e documented in the study subje ctsâ€™ case report forms and in 
their study binder.
The total volume of blood coll ected for pharmacokinetic studies , 100-120 mL, represents < 
5% of the total blood volume for a [ADDRESS_1253645], during a 28-d ay treatment cycle.  As 
pharmacokinetic data becomes ava ilable during the course of the  trial, it may be necessary to 
modify the number of samples or the times at which they are col lected to more accurately 
define the plasma concentration-time profile of the drug.  Howe ver, the cumulative volume of 
blood collected for pharmacokine tic sampling will not exceed 24 0 mL, or approximately 5% 
of the total volum e of a [ADDRESS_1253646] 4 weeks  of study treatment.  
*Computer files for dose administr ation and sample collection t ime forms and specimen tube 
labels will be placed in a subdirectory located on a secure net work server.  All members of the 
clinical, laboratory, and administrative staff involved with ph ase Ib studies will be given read-
only access to this subdirectory.  The files are placed under t he following subdirectories:  
PK_Time_Forms; PK_Tube_Labels.  Files for the PK time forms are  printed directly from the 
file stored on the network server for each subject study.  Sinc e changes may be periodically 
made to these forms, they cannot b e copi[INVESTIGATOR_894653] c omputers and staff members 
are instructed not to make photo copi[INVESTIGATOR_894654].  The PK_ Tube_Label files are 
templates, and the files are cop ied to user computers and the l imited informati on pertaining to 
each subject studied, typi[INVESTIGATOR_894655]., is added  by [CONTACT_894680], then 
printed onto adhesive-backed labels.  Hand-written information on sample tube labels is 
absolutely prohibited.  There are separate sets of labels for b lood collection vials and sample 
storage tubes.  Blood collect ion vials are prelabeled.  
Time points will be determined as the difference between the mi dpoint of the blood collection 
interval and starting time of dose administration.  Concentrati on-time profiles of BBI608 and 
paclitaxel will be analyzed by [CONTACT_130171]/or nonlinear least squares 
regression using WinNonlin (Scientific Consulting, Inc.).  Phar macokinetic parameters and 
variables will be calculated according to standard equations.
*These instructions may require  modification based on updates t o best practices
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 48Pharmacokinetic Sample Colle ction:  on Day 16 in CYCLE 1 ONLY
Cycle 
No.ProcedureSample 
No.Desired Time
1 Draw blood sample PK-01 -5 min
Start BBI608 administration 0 min
Draw blood sample PK-02 30 min
Draw blood sample PK-03 60 min
Draw blood sample PK-04 120 min
Draw blood sample PK-05 175 min
Draw blood sample PK-06 210 min
Draw blood sample PK-07 235 min
Draw blood sample PK-08 250 min
Draw blood sample PK-09 270 min
Draw blood sample PK-10 300 min
Draw blood sample PK-11 360 min
Draw blood sample PK-12 420 min
Draw blood sample PK-13 475 min
Draw blood sample PK-14 510 min
Draw blood sample PK-15 540 min
Draw blood sample PK-16 600 min
Draw blood sample PK-17 660 min
Draw blood sample(pre-dose) PK-18 720 min
Start BBI608 administration 720 min
Pharmacokinetic Sample Colle ction:  on Day 17 in CYCLE 1 ONLY
Cycle 
No.ProcedureSample 
No.Desired Time
1 Draw blood sample PK-01 -5 min
Start BBI608 administration 0 min
Draw blood sample PK-02 30 min
Draw blood sample PK-03 60 min
Draw blood sample PK-04 120 min
Draw blood sample PK-05 175 min
Start Paclitaxel infusion 180 min
Draw blood sample PK-06 210 min
Draw blood sample PK-07 235 min
Draw blood sample PK-08 250 min
Draw blood sample PK-09 270 min
Draw blood sample PK-10 300 min
Draw blood sample PK-11 360 min
Draw blood sample PK-12 420 min
Draw blood sample PK-13 475 min
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 49Draw blood sample PK-14 510 min
Draw blood sample PK-15 540 min
Draw blood sample PK-16 600 min
Draw blood sample PK-17 660 min
Draw blood sample(pre-dose) PK-18 720 min
Start BBI608 administration 720 min
Confidential Page: 5017APPENDIX E: TUMOR BIOPSIES
Instructions for Collectin g, Processing and Shippi[INVESTIGATOR_894656]:Archival tissue samples should be  collected from all patients e nrolled in the clinical trial if they 
are available. Submission of par affin embedded tissue blocks to [LOCATION_011] Biomedical is 
preferred; however, if tumor blocks are not available, 20 positi vely charged, unstained tissue 
slides at 5 micron thickness should be sent to [LOCATION_011] Biomedica l. Archive tissue labels should 
be coded with the protocol number,  study site number, the patien tâ€™s initials and the patient 
number.  Paraffin embedded tissue blocks or prepared tissue sli des should be shipped by 
[CONTACT_894681] a t the address listed below.
Fresh Tumor Biopsies:Patients who are identified by [CONTACT_458] [INVESTIGATOR_130136] a lesion, which could be 
biopsied with a minimally invasive technique, will be asked to sign an additional consent.  
Tumor biopsy samples should be collected at baseline and [ADDRESS_1253647] of 
BBI608 on cancer stem cells. These samples will be used for res earch purposes only. Tumor 
biopsies for analysis should be collected by [CONTACT_130173].  
Tumor specimen samples should be processed sterilely into three  parts: fixed, frozen, and 
fresh.  
Fixed Tumor Biopsies fo r Immunohistochemistry 
The sample should be processed to yield paraffin embedded tissue s by [CONTACT_5035][INVESTIGATOR_894657] o perating procedures.  The samp les should be labeled and 
coded with the protocol number, study site number, the patientâ€™ s initials, the patient number 
and the sample collection date and time. The paraffin embedded tissue blocks should be 
shipped to [LOCATION_011] Biomedical a t the address listed below.
Fresh and Frozen Tumor Biops y for cancer stem cell assays
Tumor biopsies for the analysis of the effect of BBI608 on canc er stem cells should be collected 
by [CONTACT_894682].  Once the biopsy tissue is obtained, 
half of the biopsy tissue should be immediately a nd sterilely p laced into CSC transport media 
provided by [CONTACT_67456], st ored and shipped at 4ÂºC.  Over night shipment should be 
arranged on the same day as the biopsy is performed.  A label s hould be affixed to all sample 
tubes containing with the protoco l number, study site number, t he patientâ€™s initials, the patient 
number and the sample collection date and time. The other half should be immediately snap-
frozen in liquid nitrogen, and then transferred to a polypropyl ene microcentrifuge cryogenic 
tube. The tissue sample should then be stored at Â”-70ÂºC until being shipped to [LOCATION_011] 
Biomedical on dry ice to t he address listed below.   
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 51Shippi[INVESTIGATOR_22026]:
Please ship all tumor samples to the following address:
Haruhisa IguchiDiscovery Research Group[LOCATION_011] Biomedical, Inc.640 Memorial DriveCambridge, MA, [ZIP_CODE] [LOCATION_003]Phone: 617-674-6800Fax: 617-674-8662Email: higuchi@bos tonbiomedical.com
On the day that specimens are se nt to [LOCATION_011] Biomedical, please  contact [CONTACT_894683], fax or email to notify what is being sent and when th e shipment is expected to arrive.p
Iguchi Haruhisa a I
,
-6800g,
617--674-
[PHONE_18559]
tonbiomedical.com higuchi @@bost
Confidential Page: 5218 APPENDIX F: PACLITAXEL PRODUCT LABEL
Please refer to the package insert.
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 5319 SPONSOR SIGNATURE
[CONTACT_2759]: A Phase Ib/II Clinical Study of BBI608 Administered with 
Paclitaxel in Adult Patients with Advanced Malignancies
Study Number: BBI608-[ADDRESS_1253648] to critical review and has been approved by [CONTACT_1034].  The 
following personnel contributed t o writing and/or approving thi s protocol:
Signed: __________________________________ Date: ______________ _______
Dirk Huebner, MD
Vice President, Head of Development[LOCATION_011] Biomedical, Inc. _______________
Dirk H uebner, MD,
Vice President, Head of Development
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 5420 INVESTIGATORâ€™S SIGNATURE
[CONTACT_2759]: A Phase Ib/II Clinical Study of BBI608 Administered with 
Paclitaxel in Adult Patients with Advanced Malignancies
Study Number: BBI608-[ADDRESS_1253649] the study as described in the protocol. 
Printed Name:_____________________________________
Signature: _________________________________________Date: _____ _______________
[LOCATION_011] Biomedical, Inc 10 May 2018
BBI608-201 Clinical Protocol 4 Amendment #4.0
Confidential Page: 5521 REFERENCES
[Please find a list of updated reviews on cancer stem cells in all major cancer types in the June 10 special issue 
of Journal of Clinical Onc ology on cancer stem cells (J Clin Oncol. 2008 Jun 10;26(17)).] 
Boman BM, and Wicha MS. (2008). â€œCancer Stem Cells: A Step Towar d the Cure.â€ J Clin Oncol 26(17):2795-
2799.
Lobo N, Shimono Y, et al. (2007). " The Biology of Cancer Stem Ce lls." Annu Rev Cell Dev Biol 23: 675-699.
Chandesris MO, et al. (2012). â€œAu tosomal dominant STAT3 deficie ncy and hyper-IgE syndrome: molecular, 
cellular, and clinical features f rom a French national survey.â€  Medicine 91(4):e1-19.
Eisenhauer E, Therasse P, et al. (2009) â€œNew Response Evaluatio n Criteria in Solid Tumours: Revised RECIST 
Guideline (version 1.1).â€ Eur J Cancer 45(2): 228-47.
Lemma G, Lee J, et al. (2011). â€œPhase II Study of Carboplatin a nd Paclitaxel in Advanced Thymoma and 
Thymic Carcinoma.â€ J Clin Oncol 29(15): 2060-65.